Related Experiment Video

Updated: Oct 18, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Main differences between two highly effective lipid-lowering therapies in subclasses of lipoproteins in patients with

Leticia C S Pinto1, Ana P Q Mello1, Maria C O Izar1

  • 1Escola Paulista de Medicina, Setor de Lípides, Aterosclerose e Biologia Vascular, Universidade Federal de São Paulo, UNIFESP, Rua Loefgren 1350, São Paulo, SP, 04040-001, Brazil.

Lipids in Health and Disease
|September 30, 2021
PubMed

Insights

Simvastatin plus ezetimibe improved atherogenic lipoprotein subfractions more effectively than rosuvastatin in heart attack patients. This suggests a potential benefit for residual cardiovascular risk despite similar overall lipid profiles.

Area of Science:

  • Cardiology
  • Lipid Metabolism
  • Pharmacotherapy

Background:

  • Small, dense low-density lipoprotein (LDL) subfractions are linked to atherosclerotic cardiovascular disease.
  • This study investigated the impact of two potent lipid-lowering therapies on atherogenic lipoprotein subclasses in ST-segment elevation myocardial infarction (STEMI) patients.

Purpose of the Study:

  • To compare the effects of simvastatin plus ezetimibe versus rosuvastatin on LDL and intermediate-density lipoprotein (IDL) subfractions in STEMI patients.
  • To assess if differences in lipoprotein subfractions contribute to residual cardiovascular risk.

Main Methods:

  • 101 first-time STEMI patients were randomized to receive either simvastatin 40mg + ezetimibe 10mg or rosuvastatin 20mg daily for 30 days.
  • LDL and IDL subfractions were analyzed using polyacrylamide gel electrophoresis (Lipoprint System) on days 1 and 30.
  • Changes in subfractions were compared between the two treatment groups.

Main Results:

  • Both therapies yielded similar classic lipid profiles and achievement of lipid goals at 30 days.
  • Simvastatin plus ezetimibe demonstrated a more significant reduction in cholesterol content within atherogenic LDL and IDL subclasses compared to rosuvastatin (p=0.043 and p=0.047, respectively).

Conclusions:

  • Simvastatin plus ezetimibe therapy resulted in a more favorable lipoprotein subfraction profile than rosuvastatin monotherapy.
  • These improvements in lipoprotein subclasses, despite similar overall lipid profiles, may help mitigate residual cardiovascular risk.
Abstract

More Related Videos

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.8K
Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

11.0K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
966
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
66
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
71
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
53
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
51
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
134